Get started

Day One Biopharmaceuticals (United States)

Homepage: dayonebio.com
Alternate names: Day One, Day One Biopharmaceuticals, Day One Biopharmaceuticals, Inc.
ROR: 03hz16t86
OpenAlex ID: I4405264990
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
2023 · Lindsay B. Kilburn, Dong-Anh Khuong-Quang, et al. · Nature Medicine · 223
PDF
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
2024 · Cornelis M. van Tilburg, Lindsay B. Kilburn, et al. · BMC Cancer · 76
PDF
The current landscape of immunotherapy for pediatric brain tumors
2022 · Eugene I. Hwang, Elias J. Sayour, et al. · Nature Cancer · 65
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies
2021 · Andrew D.J. Pearson, Elly Barry, et al. · European Journal of Cancer · 56
PDF
ACCELERATE – Five years accelerating cancer drug development for children and adolescents
2022 · Andrew D.J. Pearson, Susan L. Weiner, et al. · European Journal of Cancer · 54
PDF
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
2023 · Drew W. Rasco, Theresa Medina, et al. · Cancer Chemotherapy and Pharmacology · 46
PDF
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition
2024 · Patricia O’Hare, Tabitha Cooney, et al. · Neuro-Oncology · 31
The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions
2022 · Bram De Wilde, Elly Barry, et al. · Journal of Clinical Oncology · 23
PDF
ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2023 · Anne-Florence Blandin, Ross Giglio, et al. · Clinical Cancer Research · 21
PDF
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
2024 · Karsten Nysom, Lindsay B Kilburn, et al. · Neuro-Oncology · 17
PDF
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment
2022 · Franciele C. Kipper, Mark W. Kieran, et al. · Cancer and Metastasis Reviews · 17
The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective
2025 · Martin J van den Bent, Timothy F Cloughesy, et al. · Neuro-Oncology · 13
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2025 · Andrew DJ Pearson, Sabine Mueller, et al. · European Journal of Cancer · 13
PDF
Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation
2025 · Shubhra Rastogi, Samantha Perino, et al. · Cancer Research Communications · 12
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.
2023 · Lindsay Baker Kilburn, Dong-Anh Khuong-Quang, et al. · Journal of Clinical Oncology · 11
PDF
Ctni-68. Firefly-1 (pnoc026): Phase 2 Study of Pan-raf Inhibitor Tovorafenib in Pediatric and Young Adult Patients With Raf-altered Recurrent or Progressive Low-grade Glioma or Advanced Solid Tumors
2022 · Lindsay Kilburn, Daniel Landi, et al. · Neuro-Oncology · 11
PDF
614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification
2024 · M. Vieito, E. Garralda, et al. · Annals of Oncology · 9
PDF
The 8th International RASopathies Symposium : Expanding research and care practice through global collaboration and advocacy
2023 · Elizabeth I. Pierpont, Anton M. Bennett, et al. · American Journal of Medical Genetics Part A · 9
PDF
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion
2023 · Katharine Offer, Michael T. McGuire, et al. · JCO Precision Oncology · 9
PDF
Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records
2024 · Susan Zelt, Tabitha Cooney, et al. · Neuro-Oncology Practice · 7
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
2024 · Lindsay B. Kilburn, Dong-Anh Khuong-Quang, et al. · Nature Medicine · 7
PDF
Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials
2024 · Ashley S. Margol, Annette M. Molinaro, et al. · Journal of Clinical Oncology · 6
Diagnostics and prospective outcome of a diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters after surgical resection (DGONC): a case report
2022 · Chelsea Howie, Tahani Ahmad, et al. · Neuro-Oncology Advances · 6
FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.
2021 · Lindsay Baker Kilburn, Nada Jabado, et al. · Journal of Clinical Oncology · 6
Emiltatug ledadotin (Emi-Le), a B7-H4–directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis.
2026 · Glenn J. Hanna, Guilherme Rabinowits, et al. · Journal of Clinical Oncology · 5
PDF
Works count: 61
Citation count: 2,978
Year
Topic
Type